Priapism: Pathogenesis, epidemiology, and management

Journal of Sexual Medicine

Volumn 7, Issue 1 PART 2, 2010, Pages 476-500

  Broderick, Gregory A ^a   Kadioglu, Ates ^b   Bivalacqua, Trinity J ^c   Ghanem, Hussein ^d   Nehra, Ajay ^e   Shamloul, Rany ^d,f,g  

^a MAYO CLINIC   (United States)

^b ISTANBUL UNIVERSITY   (Turkey)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d CAIRO UNIVERSITY   (Egypt)

^e Mayo Clinic   (United States)

^f QUEEN S UNIVERSITY   (Canada)

^g UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Ischemic priapism; Nonischemic priapism; Penile embolization; Penile shunt; Priapism; Prolonged erection; Sickle cell priapism; Stuttering priapism

Indexed keywords

ADRENALIN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIANDROGEN; BACLOFEN; DIETHYLSTILBESTROL; DIGOXIN; EPHEDRINE; ESTROGEN; ETILEFRINE; GABAPENTIN; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; GOSERELIN; HYDROXYUREA; KETOCONAZOLE; LEUPRORELIN; METARAMINOL; NORADRENALIN; PAPAVERINE; PHENTOLAMINE; PHENYLEPHRINE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTAGLANDIN E1; PSEUDOEPHEDRINE; SILDENAFIL; TADALAFIL; TERBUTALINE; UNINDEXED DRUG; VASOACTIVE AGENT;

ANAMNESIS; ARTICLE; ARTIFICIAL EMBOLISM; BEDTIME DOSAGE; BLOOD TRANSFUSION; CLINICAL TRIAL; COMPRESSION THERAPY; CRYOTHERAPY; DOPPLER ECHOGRAPHY; DROWSINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSPEPSIA; ERECTILE DYSFUNCTION; EVENING DOSAGE; EVIDENCE BASED MEDICINE; FATIGUE; FLUSHING; HORMONAL THERAPY; HUMAN; INCIDENCE; LABORATORY TEST; MYALGIA; NAUSEA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATHOPHYSIOLOGY; PENILE BLOOD FLOW; PENIS ERECTION; PENIS INJURY; PHOTOSENSITIVITY; PHYSICAL EXAMINATION; PREVALENCE; PRIAPISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHINITIS; SHUNTING; SICKLE CELL ANEMIA; SIDE EFFECT; SIGNAL TRANSDUCTION;

EID: 74049114523     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2009.01625.x     Document Type: Article

References (138)

1. Spycher MA, Hauri D. The ultastructure of the erectile tissue in priapism. J Urol 1986, 135:142-7.
2. Serjeant GR, de Ceulaer K, Maude GH. Stilboestrol and stuttering priapism in homozygous sickle-cell disease. Lancet 1985, 2:1274-6.
3. Tripe JW. Case of continued priapism. Lancet 1845, 2:8.
4. Hinman F. Priapism: Report of case in a clinical study of the literature with reference to its pathogenesis and surgical treatments. Ann Surg 1914, 60:689-716.
5. Hinman F. Priapism: Reasons for failure of therapy. J Urol 1960, 83:420-8.
6. Hauri D, Spycher M, Brühlmann W. Erection and priapism: A new physiopathological concept. Urol Int 1983, 38:138-41.
7. Emond AM, Holman R, Hayes RJ, Serjeant GR. Priapism and impotence in homozygous sickle cell disease. Arch Intern Med 1980, 140:1437-7.
8. Burt FB, Schimer HK, Scott WW. A new concept in the management of priapism. J Urol 1960, 83:60-1.
9. Pohl J, Pott B, Kleinhans G. Priapism: A three-phase concept of management according to etiology and prognosis. Br J Urol 1986, 58:113.
10. Hoover NG, Fortenberry JD. Use of antivenin to treat priapism after a black widow spider bite. Pediatrics 2004, 114:128-9.
11. Lue TF, Walsh PC, Retik AB, Vaughan ED, Wein AJ, Kavoussi AR, Novick AC. Physiology of penile erection and pathophysiology of erectile dysfunction and priapism. Campbell's urology 2002, 1610-96. In, eds., Philadelphia, W.B. Saunders
12. Nelson JH, Winter CC. Priapism: Evolution of management in 48 patients in a 22 years series. J Urol 1977, 117:455-8.
13. Tarry WF, Duckett JW, Snyder H. Urological complications of sickle cell disease in a pediatric population. J Urol 1987, 138:592.
14. Adeyoju AB, Olujohungbe AB, Morris J, Yardumian A, Bareford D, Akenova A, Akinyanju O, Cinkotai K, O'Reilly PH. Priapism in sickle-cell disease; incidence, risk factors and complications-An international multicentre study. BJU Int 2002, 90:898-902.
15. Aliyu ZY, Kato GJ, Taylor J, Babadoko A, Mamman AI, Gordeuk VR, Gladwin MT. Sickle cell disease and pulmonary hypertension in Africa: A global perspective and review of epidemiology, pathophysiology, and management. Am J Hematol 2008, 83:63-70.
16. Morris CR, Kato GJ, Pojakovic M. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension and mortality in sickle cell disease. JAMA 2005, 294:81-90.
17. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequela of intravascular hemolysis and extracellular plasma hemoglobin: A novel mechanism of human disease. JAMA 2005, 293:1652-62.
18. Kato GJ, Gladwin MT, Steinber MH. Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 2007, 21:37-47.
19. Kato GJ, McGowan VR, Machado RF, Little JA, Taylor VJ, Morris CR. Lactate dehydrogenase as a biomarker of hemolysis associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension and death in patents with sickle cell disease. Blood 2006, 107:2279-85.
20. Merritt AL, Haiman C, Henderson SD. Myth: Blood transfusion is effective for sickle cell anemia associated priapism. CJEM 2006, 8:119-22.
21. Birnbaum BF, Pinzone JJ. Sickle cell trait and priapism: A case report and review of the literature. Cases J 2008, 1:429.
22. Larocque MA, Cosgrove MD. Priapism: A review of 46 cases. J Urol 1974, 112:770-2.
23. Broderick GA, Lue TF, Walsh PC, Retik AB, Vaughan ED, Wein AJ, Kavoussi AR, Novick AC. Evaluation and nonsurgical management of erectile dysfunction and priapism. Campbell's urology 2002, 1619-71. In, eds., Philadelphia, W.B. Saunders
24. Junemann KP, Persson-Junemann C, Alken P. Pathophysiology of erectile dysfunction. Semin Urol 1990, 8:80-93.
25. Porst H. The rational for prostaglandin E1 in erectile failure: A survey of worldwide experience. J Urol 1996, 155:802-15.
26. Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int J Impot Res 1998, 10:69-73.
27. Montorsi F, Verheyden B, Meuleman E. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol 2004, 45:339-45.
28. McVary KT, Roehrborn CG, Kaminetsky JC. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007, 177:1401-7.
29. Aoyagi T, Hayakawa K, Miyaji K, Ishikawa H, Hata M. Sildenafil induced priapism. Bull Tokyo Dent Coll 1999, 40:215-7.
30. Sur RL, Kane CJ. Sildenafil citrate-associated priapism. Urology 2000, 55:950.
31. Kassim AA, Fabry ME, Nagel RL. Acute priapism associated with the use of sildenafil in a patient with sickle cell trait. Letter to the editor. Blood 2000, 95:1878-9.
32. Goldmeier D. Prolonged erection produced by dihydrocodeine and sildenafil. BMJ 2002, 524:1555.
33. McMahon CG. Priapism associated with concurrent use of phosphodiesteras inhibitor drugs and intracavernous injection therapy. Int J Impot Res 2003, 15:383-4.
34. Wilt TJ, Fink HA. Is antidepressant plus sildenafil a recipe for priapism? Postgrad Med 2004, 116:11-2.
35. Galatti L, Fioraavanti A, Salvo F. Interaction between tadalafil and itraconazole. Ann Pharmacother 2005, 39:200.
36. Kumar R, Jindal L, Seth A. Priapism following oral sildenafil abuse. Natl Med J India 2005, 18:49.
37. King SH, Hallock M, Strote J, Wessells H. Tadalafil associated priapism. Urology 2005, 66:432e15-8.
38. Wills B, Albinson C, Wahl M, Clifton J. Sildenafil citrate ingestion and prolonged priapism and tachycardia in a pediatric patient. Clin Toxicol 2007, 45:798-800.
39. Chow K, Payne S. The pharmacological management of intermittent priapismic states. BJU Int 2008, 102:1515-21.
40. de Jesus LE, Dekermacher S. Priapism in children: Review of pathophysiology and treatment. J Pediatr (Rio J) 2009, 85:194-200.
41. Witt MA, Goldstein I, Saenz de Tejada I, Greenfield A, Krane RJ. Traumatic laceration of intracavernosal arteries: The pathophysiology of nonischemic, high flow arterial priapism. J Urol 1990, 143:129-32.
42. Dubocq FM, Tefilli MV, Grignon DJ, Ponte JE, Dhabuwala CB. High flow malignant priapism with isolated metastasis to the corpora cavernosa. Urology 1998, 51:324-6.
43. Brock G, Breza J, Lue TF, Tanagho EA. High flow priapism: A spectrum of disease. J Urol 1993, 150:969-71.
44. Burgu B, Talas H, Erdeve O, Karagol BS, Fitoz S, Soygur TY. Approach to newborn priapism: A rare entity. J Pediatr Urol 2007, 3:509-11.
45. Liguori G. High flow priapism secondary to Nesbit operation: Management by percutaneous embolization and colour Doppler guided compression. Int J Impot Res 2005, 17:304-6.
46. Wolf JS, Lue TF. High flow priapism and glans hypervascularization following deep dorsal vein arterialization for vasculogenic impotence. Urol Int 1992, 49:227-9.
47. McMahon CG. High flow priapism due to an arterial-sinusoidal fistula complicating initial veno-occlusive priapism. Int J Impot Res 2002, 14:195-6.
48. Rodriguez J, Cuadrado JM, Frances A, Franco E. High flow priapism as a complication of veno-occlusive priapism. Two case reports. Int J Impot Res 2006, 18:215-7.
49. Bertolotto M, Ciampalini S, Martingano P, Mucelli FP. High flow priapism complicating ischemic priapism following iatrogenic laceration of the dorsal artery during a Winter procedure. J Clin Ultrasound 2009, 37:61-4.
50. Seftel A, Haas CA, Brown SL, Herbener TE, Sands M, Lipuma J. High flow priapism complicating veno-occlusive priapism: Pathophysiology of recurrent idiopathic priapism? J Urol 1998, 159:1300-1.
51. Wallace CJ, Hoag N, Pommerville PJ, Huk ME. Recurrent idiopathic high-flow priapism treated with selective arterial embolization after repeated initial treatments for low-flow priapism. Can Urol Assoc J 2009, 3:60-3.
52. Cruz Guerra NA, Pozo Mengual B, Perales Cespedes MP, Allona Almagro A, Saenz Medine J, Tarroc Blanco A. Metachronous recurrence of idiopathic high flow priapism. Arch Esp Urol 2004, 57:82-4.
53. Ricciardi R, Bhatt GM, Cynamon J, Bakal CW, Melman A. Delayed high-flow priapism: Pathophysiology and management. J Urol 1993, 149:119-21.
54. Leal J, Walker D, Egan EA. Idiopathic priapism in the newborn. J Urol 1978, 120:376.
55. Shapiro SR. Idiopathic priapism in the newborn. J Urol 1979, 121:838.
56. Amlie RN, Borgeois B, Huxtable R. Priapism in preterm infant. Urology 1977, 9:558-9.
57. Walker JR, Casale AJ. Prolonged penile erection in the newborn. Urology 1997, 50:796-9.
58. Meijer B, Bakker HHR. Management of priapism in the newborn. Urology 2003, 61:224.
59. Pietras JR, Cromie WJ, Duckett JW. Ketamine as a detumescence agent during hypospadias repair. J Urol 1979, 121:654.
60. Hatzichristou D, Salpiggidis G, Hatzimouratidis K, Apostolidis A, Tzortzis V, Bekos A, Saripoulos D. Management strategy for arterial priapism: Therapeutic dilemmas. J Urol 2002, 168:2074-7.
61. Broderick GA, Gordon D, Hypolite J, Levin RM. Anoxia and corporal smooth muscle dysfunction: A model for ischemic priapism. J Urol 1994, 151:259-62.
62. Broderick GA, Harkaway R. Pharmacologic erection: Time-dependent changes in the corporal environment. Int J Impot Res 1994, 6:9-16.
63. Muneer A, Cellek S, Dogan A, Kell PD, Ralph DJ, Minhas S. Investigation of cavernosal smooth muscle dysfunction in low flow priapism using an in vitro model. Int J Impot Res 2005, 17:10-8.
64. Saenz de Tejada I, Kim NN, Daley JT, Royai R, Hypolite J, Broderick GA, Garcia-Diaz F, Levin R. Acidosis impairs rabbit trabecular smooth muscle contractility. J Urol 1997, 157:722-6.
65. Munarriz R, Park K, Huang YH, Saenz de Tejada I, Moreland RB, Goldstein I, Traish AM. Reperfusion of ischemic corporal tissue: Physiologic and biochemical changes in an animal model of ischemic priapism. Urology 2003, 62:760-4.
66. Jin YC, Gam SC, Jung JH, Hyun JS, Chang KC, Hyun JS. Expression and activity of heme oxygenase-1 in artificially induced low-flow priapism in rat penile tissues. J Sex Med 2008, 5:1876-82.
67. Moreland RB, Traish A, McMillin MA, Smith B, Goldstein I, Saenz de Tejada I. PGE1 suppresses the induction of collagen synthesis by transforming growth factor-beta 1 in human corpus cavernosum smooth muscle. J Urol 1995, 153:826-34.
68. Bivalacqua TJ, Diner EK, Novak TE, Vohra Y, Sikka SC, Champion HC, Kadowitz PJ, Hellstrom WJ. A rat model of Peyronie's disease associated with a decrease in erectile activity and an increase in inducible nitric oxide synthase protein expression. J Urol 2000, 163:1992-8.
69. Jeong WI, Do SH, Yun HS, Song BJ, Kim SJ, Kwak WJ, Yoo SE, Park HY, Jeong KS. Hypoxia potentiates transforming growth factor-beta expression of hepatocyte during the cirrhotic condition in rat liver. Liver Int 2004, 24:658-68.
70. Beuzard Y. Transgenic mouse models of sickle cell disease. Curr Opin Hematol 1996, 3:150-5.
71. Bivalacqua TJ, Musicki B, Champion HC, Burnett AL, Carson CC, Kirby RS, Goldstein I, Wyllie MG. Phosphodiesterase type 5 inhibitor therapy for priapism. Textbook of erectile dysfunction 2009, 428-33. In, eds., 2nd, edition, New York, Informa Healthcare
72. Mi T, Abbasi S, Zhang H, Uray K, Chunn JL, Xia LW, Molina JG, Weisbrodt NW, Kellems RE, Blackburn MR, Xia Y. Excess adenosine in murine penile erectile tissues contributes to priapism via A2B adenosine receptor signaling. J Clin Invest 2008, 118:1491-501.
73. Bivalacqua TJ, Liu T, Musicki B, Champion HC, Burnett AL. Endothelial nitric oxide synthase keeps erection regulatory function balance in the penis. Eur Urol 2007, 51:1732-40.
74. Bivalacqua TJ, Champion HC, Mason W, Musicki B, Burnett AL. Long-term phosphodiesterase type 5 inhibitor therapy reduces priapic activity in transgenic sickle cell mice. J Urol 2006, 175:387.
75. Bivalacqua TJ, Musicki B, Hsu LL, Gladwin MT, Burnett AL, Champion HC. Establishment of a transgenic sickle cell mouse model to study the pathophysiology of priapism. J Sex Med 2009, 6:2494-504.
76. Champion HC, Bivalacqua TF, Takimoto E, Kass DA, Burnett AL. Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci USA 2005, 102:1661-6.
77. Bivalacqua TJ, Burnett AL. Priapism: New concepts in the pathophysiology and new treatment strategies. Curr Urol Rep 2006, 7:497-502.
78. Lin G, Xin ZC, Lue TF, Lin CS. Up and down-regulation of phosphodiesterase-5 as related to tachyphylaxis and priapism. J Urol 2003, 170:S15-9.
79. Burnett AL, Bivalacqua TJ. Priapism: Current principles and practice. Urol Clin North Am 2007, 34:631-42.
80. Montague DK, Jarow J, Broderick GA, Dmochowsky RR, Heaton JP, Lue TF, Nehra A, Sharlip ID. Urological association guideline on the management of priapism. J Urol 2003, 170:1318-24.
81. Burnett AL, Walsh PC, Retik AB, Vaughan ED, Wein AJ, Kavoussi AR, Novick AC. Priapism. Campbell's urology 2004, 839-49. In, eds., Philadelphia, W.B. Saunders
82. Kirkham A, Illing RO, Minahas S, Allen C. MR imaging of nonmalignant penile lesions. RadioGraphics 2008, 28:837-53.
83. Ralph DJ, Garaffa G, Muneer A, Freeman A, Rees R. The immediate insertion of a penile prosthesis for acute ischaemic priapism. Eur Urol 2009, 56:1033-38.
84. Lowe FC, Jarow JP. Placebo-controlled study of oral terbutaline in management of prostaglandin E1 induced prolonged erections. J Urol 1993, 42:51-3.
85. Ateyah A, Rahman El-Nashar A, Zohdy W, Arafa M, Saad El-Den H. Intracavernosal irrigation by cold saline as a simple method of treating iatrogenic prolonged erection. J Sex Med 2005, 2:248-53.
86. Muneer A, Minhas S, Freeman A, Kumar P, Ralph DJ. Investigating the effects of high-dose phenylephrine in the management of prolonged ischaemic priapism. J Sex Med 2008, 5:2152-9.
87. Munnarriz R, Wen CC, McAuley I, Goldstein I, Traish A, Kim N. Management of ischemic priapism with high-dose intracavernosal phenylephrine: From bench to bedside. J Sex Med 2006, 3:918-22.
88. Pryor J, Akkus E, Alter G, Jordan G, Lebret T, Levine L, Mulhall J, Perovic S, Ralph D, Stackl W. Priapism. J Sex Med 2004, 1:116-20.
89. Davila HH, Parker J. Subarachnoid hemorrhage as complication of phenylephrine injection for the treatment of ischemic priapism in sickle cell disease patient. J Sex Med 2008, 5:1025-8.
90. Rogers ZR. Priapism in sickle cell disease. Hematol Oncol Clin North Am 2005, 19:917-28.
91. Mantadakis E, Ewalt DH, Cavender JD. Outpatient penile aspiration and epinephrine irrigation for young patients with sickle cell anemia and prolonged priapism. Blood 2000, 95:78-82.
92. Teloken C, Ribeiro EP, Chammas M, Teloken PE, Souto CA. Intracavernosal etilefrine self-injection therapy for recurrent priapism. Urology 2005, 65:1002.
93. Virag R, Buchi D, Lee K, Galacteros E. Preventive treatment of sickle cell disease with oral and self-administered intracavernous injection of etilefrine. Urology 1996, 47:777-81.
94. Okpala I, Westerdale N, Jegede T, Cheung B. Etilefrine for the prevention of priapism in adult sickle cell disease. Br J Haematol 2002, 118:918-21.
95. Gbadoe AD, Assimadi JK, Segbena YA. Short period of administration of diethylstilbestrol in stuttering priapism in sickle cell anemia. Am J Hematol 2002, 69:297-8.
96. Chinegwundoh FI, Anie KA. Treatments for priapism in boys and men with sickle cell disease. Cochrane Database Syst Rev 2004, 18:CD004198.
97. Shamloul R, el Nashaar A. Idiopathic stuttering priapism treated successfully with low-dose ethinyl estradiol: A single case report. J Sex Med 2005, 2:732-4.
98. Levine LA, Guss SP. Gonadotropin releasing hormone analogues in the treatment of sickle cell anemia-associated priapism. J Urol 1993, 150:475-7.
99. Steinberg J, Eyre RC. Management of recurrent priapism with epinephrine self-injection and gonadotropin-releasing hormone analogue. J Urol 1995, 153:152-3.
100. Costabile RA. Successful treatment of stutter priapism with an antiandrogen. Tech Urol 1998, 4:167-8.
101. Dahm P, Rao DS, Donatucci CF. Antiandrogens in the treatment of priapism. Urology 2002, 59:138.
102. Yamashita N, Hisasue S, Kato R. Idiopathic stuttering priapism: Recovery of detumescence mechanism with temporal use of antiandrogen. Urology 2004, 63:1182-4.
103. Bitran D, Miller SA, McQuade DB. Inhibition of sexual reflexes by lumbosacral injection of a GABA-B agonist in the male rat. Pharmacol Biochem Behav 1988, 31:657-66.
104. Paredes RG, Agmo A. The GABA-B antagonist CGP 35348 inhibits the effects of baclofen on sexual behavior and motor coordination. Brain Res Bull 1995, 36:495-7.
105. Vaidyanathan S, Watt JW, Singh G, Hughes PL, Selmi F, Oo T, Soni BM, Sett P. Management of recurrent priapism in a cervical spinal cord injury patient with oral baclofen therapy. Spinal Cord 2004, 42:134-5.
106. Denys P, Mane M, Azouvi P. Side effects of chronic intrathecal baclofen on erection and ejaculation in patients with spinal cord lesions. Arch Phys Med Rehabil 1998, 79:494-6.
107. Rourke KF, Fischler AH, Jordan GH. Treatment of recurrent idiopathic priapism with oral baclofen. J Urol 2002, 168:2552-3.
108. D'Aleo G, Rifici C, Kofler M, Saltuari L, Bramanti P. Favorable response to intrathecal, but not oral, baclofen of priapism in a patient with spinal cord injury. Spine 2009, 34:E127-9.
109. Bialecki ES, Bridges KR. Sildenafil relieves priapism in patients with sickle cell disease. Am J Med 2002, 113:252.
110. Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism. J Sex Med 2006, 3:1077-84.
111. Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism. Urology 2006, 67:1043-8.
112. Mulhall J, Porst H, Buvat J. Priapism-guidelines for surgical management of priapism in standard practice of sexual medicine. Standard Practice in Sexual Medicine 2006, 180-90. In, eds., Oxford, Blackwell Science
113. Pryor JP, Hehir M. The management of priapism. Br J Urol 1982, 54:751.
114. Bennett N, Mulhall J. Sickle cell disease status and outcomes of African American men presenting with priapism. J Sex Med 2008, 5:1244-50.
115. Lue TF, Pescatori ES. Distal cavernosum-glans shunts for ischemic priapism. J Sex Med 2006, 3:749-52.
116. Winter CC. Cure of idiopathic priapism: New procedure for creating fistula between glans penis and corpora cavernosa. Urology 1976, 8:389-91.
117. Ebbehoj J. A new operation for priapism. Scand J Plast Reconstr Surg 1974, 8:241.
118. Brant WO, Garcia MM, Bella AJ, Chi T, Lue TF. T-shaped shunt and intracavernous tunneling for prolonged ischemic priapism. J Urol 2009, 181:1699-705.
119. Hanafy HM, Saad SM, El-Rifaie M, Al-Ghorab MM. Early Arabian medicine: Contribution to urology. Urology 1976, 8:63-7.
120. Borrelli M, Mitre AI, Alfer Junior W, Denes FT, Wroclawski ER, Castilho LN, de Goes GM. Surgical treatment of priapism using Al-Ghorab's technique. Rev Paul Med 1983, 101:27.
121. Burnett A, Pierorazio P. Corporal " snake" maneuver: Corporoglanular shunt surgical modification for ischemic priapism. J Sex Med 2009, 6:1171-6.
122. Quackles R. Treatment of a case of priapism by cavernospongious anastomosis. Acta Urol Belg 1964, 32:5-13.
123. Sacher EC, Sayegh E, Frensilli F, Crum P, Akers R. Cavernospongiosum shunt in treatment of priapism. J Urol 1972, 108:97-100.
124. Grayhack JT, McCullough W, O'Conor VI, Trippel O. Venous bypass to control priapism. Invest Urol 1964, 1:509.
125. Barry JM. Priapism. Treatment with corpus cavernosum to dorsal vein of penis shunts. J Urol 1976, 116:754-6.
126. Nixon RG, O'Connor JL, Milam DF. Efficacy of shunt surgery for refractory low flow priapism: A report on the incidence of failed detumescence and erectile dysfunction. J Urol 2003, 170:883.
127. Chiou RK, Aggarawal H, Mues AC, Chiou CR, Boughton FL. Clinical experience and sexual function outcome of patients with priapism treated with penile cavernosal-dorsal vein shunt using saphenous vein graft. Urology 73:556-61.
128. Kandel GL, Bender LI, Grove JS. Pulmonary embolism: a complication of corpus saphenous shunt for priapism. J Urol 1968, 99:196-7.
129. Nehra A, Porst H, Buvat J. Priapism-pathophysiology and non-surgical management in standard practice in sexual medicine. Standard Practice in Sexual Medicine 2006, 174-9. In, eds., Oxford, Blackwell
130. Kuefer R, Bartsch G, Herkommer K, Krämer SC, Kleinschmidt K, Volkmer BG. Changing diagnostic and therapeutic concepts in high-flow priapism. Int J Impot Res 2005, 17:109-13.
131. Savoca G, Pietropaolo F, Scieri F, Bertolotto M, Mucelli FP, Belgrano E. Sexual function after highly selective embolisation of cavernous artery in patients with high-flow priapism: Long-term follow-up. J Urol 2004, 172:644-7.
132. Alexander Tønseth K, Egge T, Kolbenstvedt A, Hedlund H. Evaluation of patients after treatment of arterial priapism with selective micro-embolization. Scand J Urol Nephrol 2006, 40:49-52.
133. Sandock DS, Seftel AD, Herbener TE, Goldstein I, Greenfield AJ. Perineal abcess after embolization for high-flow priapism. Urology 1996, 308:48.
134. Bartsch G, Kuefer R, Engel O, Volkmer BG. High-flow priapism: Colour-Doppler ultrasound-guided supraselective embolization therapy. World J Urol 2004, 22:368-70.
135. Puppo P, Belgrano E, Germinale F, Bottino P, Giuliani L. Angiographic treatment of high-flow priapism. Eur Urol 1985, 11:397.
136. Kim KR, Shin JH, Song HY, Ko GY, Yoon HK, Sung KB, Ahn TY, Kim CW. Treatment of high-flow priapism with superselective transcatheter embolization in 27 patients: A multicenter study. J Vasc Interv Radiol 2007, 18:1222-6.
137. Ji MX, He NS, Wang P, Chen G. Use of selective embolization of the bilateral cavernous arteries for post-traumatic arterial priapism. J Urol 1994, 151:1641.
138. Berger R, Billups K, Brock G, Broderick GA, Dhabuwala CB, Goldstein I, Hakim LS, Hellstrom W, Honig S, Levine LA, Lue T, Munarriz R, Montague DK, Mulcahy JJ, Nehra A, Rogers ZR, Rosen R, Seftel AD, Shabsigh R, Steers W. Report of the American Foundation for Urologic Disease (AFUD) Thought Leader Panel for evaluation and treatment of priapism. Int J Impot Res 2001, 13(5):S39-43. suppl